{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T10:02:19Z","timestamp":1773223339738,"version":"3.50.1"},"reference-count":35,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Metastatic squamous cell carcinoma of the anus (SCCA) carries a poor prognosis, with systemic therapy remaining the standard of care. While metastasis-directed therapy improves outcomes in select gastrointestinal malignancies, the role of liver-directed intervention in metastatic SCCA remains undefined. We evaluated clinicopathologic features and oncologic outcomes of patients with liver-limited metastatic SCCA treated with curative-intent hepatic local therapy at a tertiary academic center. Methods: We conducted a retrospective cohort study of adults with histologically confirmed SCCA and liver-only metastatic disease who underwent curative-intent hepatic resection or ablation at Mayo Clinic between 1993 and 2023. Patients with extrahepatic disease or incomplete records were excluded. Demographic, tumor, treatment, and outcomes data were abstracted from electronic medical records. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan\u2013Meier method. Prognostic factors were assessed using univariate Cox proportional hazards models. Results: Twenty-five patients met inclusion criteria. Median age was 56.7 years, and 92% were female. Most patients had metachronous metastases (76%), a single hepatic lesion (56%), and unilobar disease (76%). Pre-intervention systemic therapy was administered in 52% of patients, with radiographic complete or partial responses observed in all treated patients. Liver-directed therapy consisted of surgical resection in 80% and thermal ablation in 20%. Among surgical patients, 90% achieved microscopically negative margins. With a median follow-up of 22 months, disease recurrence occurred in 80% of patients, most commonly within the liver. Median DFS was 7.27 months. Median OS from the date of liver-directed therapy was 51.3 months. On univariate analysis, poorly differentiated tumor histology was associated with inferior OS (hazard ratio 4.67, p = 0.018). No other clinicopathologic variables were significantly associated with DFS or OS. Conclusions: In this single-institution experience, carefully selected patients with liver-limited metastatic SCCA undergoing curative-intent hepatic-directed therapy achieved prolonged overall survival, substantially exceeding historical outcomes with systemic therapy alone. Despite frequent recurrence, the observed median OS exceeding four years supports consideration of liver-directed therapy within a multidisciplinary framework for patients demonstrating favorable disease biology and response to systemic treatment. Prospective studies are needed to better define patient selection and optimal integration of local and systemic therapies in the modern treatment era.<\/jats:p>","DOI":"10.3390\/curroncol33030157","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:39:08Z","timestamp":1773146348000},"page":"157","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Liver Metastasectomy in Anal Squamous Cell Carcinoma: The Mayo Clinic Experience"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2781-3047","authenticated-orcid":false,"given":"Noah","family":"Takacs","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6291-846X","authenticated-orcid":false,"given":"Conor D. J.","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32066, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishan","family":"Jethwa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Atwell","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Starlinger","sequence":"additional","affiliation":[{"name":"Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7844-5833","authenticated-orcid":false,"given":"Zhaohui","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cncr.20364","article-title":"Anal cancer incidence and survival: The surveillance, epidemiology, and end results experience, 1973\u20132000","volume":"101","author":"Johnson","year":"2004","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jnci\/djz219","article-title":"Recent Trends in Squamous Cell Carcinoma of the Anus Incidence and Mortality in the United States, 2001\u20132015","volume":"112","author":"Deshmukh","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/1055-9965.EPI-15-0044","article-title":"Anal Cancer Incidence in the United States, 1977\u20132011: Distinct Patterns by Histology and Behavior","volume":"24","author":"Shiels","year":"2015","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.14309\/01.ajg.0000702768.51346.bf","article-title":"Anal Squamous Cell Carcinoma: A Growing Threat to Women\u2019s Health and Call for Action","volume":"115","author":"Raed","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/1097-0142(20010701)92:1<77::AID-CNCR1294>3.0.CO;2-P","article-title":"Management of inguinal lymph node metastases in patients with carcinoma of the anal canal: Experience in a series of 270 patients treated in Lyon and review of the literature","volume":"92","author":"Gerard","year":"2001","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ijrobp.2013.07.035","article-title":"Anal carcinoma: Impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial","volume":"87","author":"Gunderson","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1056\/NEJM200003163421107","article-title":"Carcinoma of the anal canal","volume":"342","author":"Ryan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00001622-200007000-00011","article-title":"Anal carcinoma: Histology, staging, epidemiology, treatment","volume":"12","author":"Ryan","year":"2000","journal-title":"Curr. Opin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.surg.2023.05.028","article-title":"Characteristics, treatment, and outcomes of anal versus rectal squamous cell carcinoma, a retrospective cohort study","volume":"174","author":"Emile","year":"2023","journal-title":"Surgery"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ejso.2014.07.030","article-title":"Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"40","author":"Nilsson","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(17)30456-4","article-title":"Nodal stage migration and prognosis in anal cancer: A systematic review, meta-regression, and simulation study","volume":"18","author":"Sekhar","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/0284186X.2021.1918763","article-title":"Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer","volume":"60","author":"Slordahl","year":"2021","journal-title":"Acta Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(25)00631-2","article-title":"Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303\/InterAACT-2): A global, phase 3 randomised controlled trial","volume":"405","author":"Rao","year":"2025","journal-title":"Lancet"},{"key":"ref_15","first-page":"5","article-title":"Metastatic anal cancer: The search for cure","volume":"29","author":"Cummings","year":"2006","journal-title":"Onkologie"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S396","DOI":"10.1016\/j.jacr.2025.02.018","article-title":"ACR Appropriateness Criteria(R) Staging and Follow-up of Anal Cancer","volume":"22","author":"Horvat","year":"2025","journal-title":"J. Am. Coll. Radiol."},{"key":"ref_17","first-page":"e39","article-title":"FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer","volume":"18","author":"Mondaca","year":"2019","journal-title":"Clin. Color. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100529","DOI":"10.1016\/j.esmoop.2022.100529","article-title":"A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)","volume":"7","author":"Rao","year":"2022","journal-title":"ESMO Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2468-1253(21)00382-4","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study","volume":"7","author":"Marabelle","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1200\/JCO-25-00929","article-title":"NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab with or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal","volume":"44","author":"Morris","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.amjsurg.2020.08.016","article-title":"Role of metastasectomy for liver metastasis in stage IV anal cancer","volume":"221","author":"Goldner","year":"2021","journal-title":"Am. J. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1245\/s10434-007-9467-8","article-title":"Liver-directed surgery for metastatic squamous cell carcinoma to the liver: Results of a multi-center analysis","volume":"14","author":"Pawlik","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1308\/rcsann.2023.0005","article-title":"Systematic review of survival following liver or lung metastasectomy for metastatic anal squamous cell carcinoma","volume":"107","author":"Hurt","year":"2025","journal-title":"Ann. R. Coll. Surg. Engl."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/jso.27539","article-title":"Long-term overall survival in patients undergoing liver resection for metastatic anal squamous cell carcinoma","volume":"129","author":"Lo","year":"2024","journal-title":"J. Surg. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Rogers, J.E., Sirisaengtaksin, A., Leung, M., Morris, V.K., Xiao, L., Huey, R., Wolff, R., Eng, C., Vauthey, J.N., and Tzeng, C.-W.D. (2023). Hepatic Metastasectomy in Squamous Cell Carcinoma of the Anal Canal: A Case Series of a Curative Approach. Cancers, 15.","DOI":"10.3390\/cancers15153890"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejca.2021.07.041","article-title":"Prognostic value of high-risk human papillomavirus DNA and p16(INK4a) immunohistochemistry in patients with anal cancer: An individual patient data meta-analysis","volume":"157","author":"Obermueller","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1158\/1055-9965.EPI-19-1259","article-title":"Prognostic Significance of HPV DNA and p16(INK4a) in Anal Cancer: A Systematic Review and Meta-Analysis","volume":"29","author":"Urbute","year":"2020","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2023.41.4_suppl.1","article-title":"Circulating tumor DNA (ctDNA) for response assessment in patients with anal cancer treated with definitive chemoradiation","volume":"41","author":"Alvarez","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/oncolo\/oyac249","article-title":"Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma","volume":"28","author":"Azzi","year":"2023","journal-title":"Oncologist"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"678","DOI":"10.6004\/jnccn.2023.7031","article-title":"Prognostic and Predictive Markers for Patients with Anal Cancer","volume":"21","author":"Holliday","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1158\/1078-0432.CCR-18-2984","article-title":"Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial","volume":"25","author":"Jeannot","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2025.43.4_suppl.15","article-title":"Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II\/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort","volume":"43","author":"Shah","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jamaoncol.2025.5144","article-title":"Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated with Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)\/SWOG 80702 Phase 3 Randomized Clinical Trial","volume":"12","author":"Zhang","year":"2026","journal-title":"JAMA Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N. Engl. J. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/3\/157\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:54:38Z","timestamp":1773147278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/3\/157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["curroncol33030157"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33030157","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]}}}